Literature DB >> 21545511

Decreased plasma granulysin and increased interferon-gamma concentrations in patients with newly diagnosed and relapsed tuberculosis.

Nada Pitabut1, Surakameth Mahasirimongkol, Hideki Yanai, Chutharut Ridruechai, Shinsaku Sakurada, Panadda Dhepakson, Pacharee Kantipong, Surachai Piyaworawong, Saiyud Moolphate, Chamnarn Hansudewechakul, Norio Yamada, Naoto Keicho, Masaji Okada, Srisin Khusmith.   

Abstract

Granulysin and interferon-gamma (IFN-γ) have broad antimicrobial activity which controls Mycobacterium tuberculosis (M. tuberculosis) infection. Circulating granulysin and IFN-γ concentrations were measured and correlated with clinical disease in Thai patients with newly diagnosed, relapsed and chronic tuberculosis (TB). Compared to controls, patients with newly diagnosed, relapsed and chronic TB had lower circulating granulysin concentrations, these differences being significant only in newly diagnosed and relapsed TB (P < 0.001 and 0.004, respectively). Granulysin concentrations in patients with newly diagnosed and relapsed TB were significantly lower than in those with chronic TB (P= 0.003 and P= 0.022, respectively). In contrast, significantly higher circulating IFN-γ concentrations were found in patients with newly diagnosed and relapsed TB compared to controls (P < 0.001). The IFN-γ concentrations in newly diagnosed and relapsed patients were not significantly different from those of patients with chronic TB. However, in vitro stimulation of peripheral blood mononuclear cells (PBMCs) from patients with newly diagnosed, relapsed and chronic TB with purified protein derivative (PPD) or heat killed M. tuberculosis (H37Ra) enhanced production of granulysin by PBMCs. In vitro, stimulation of PBMCs of newly diagnosed TB patients with PPD produced greater amounts of IFN-γ than did controls, while those stimulated with H37Ra did not. The results demonstrate that patients with active pulmonary TB have low circulating granulysin but high IFN-γ concentrations, suggesting possible roles in host defense against M. tuberculosis for these agents.
© 2011 The Societies and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545511     DOI: 10.1111/j.1348-0421.2011.00348.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

Review 1.  Granulysin: killer lymphocyte safeguard against microbes.

Authors:  Farokh Dotiwala; Judy Lieberman
Journal:  Curr Opin Immunol       Date:  2019-05-18       Impact factor: 7.486

2.  Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes.

Authors:  Michael Walch; Farokh Dotiwala; Sachin Mulik; Jerome Thiery; Tomas Kirchhausen; Carol Clayberger; Alan M Krensky; Denis Martinvalet; Judy Lieberman
Journal:  Cell       Date:  2014-06-05       Impact factor: 41.582

3.  Potential function of granulysin, other related effector molecules and lymphocyte subsets in patients with TB and HIV/TB coinfection.

Authors:  Nada Pitabut; Shinsaku Sakurada; Takahiro Tanaka; Chutharut Ridruechai; Junko Tanuma; Takahiro Aoki; Pacharee Kantipong; Surachai Piyaworawong; Nobuyuki Kobayashi; Panadda Dhepakson; Hideki Yanai; Norio Yamada; Shinichi Oka; Masaji Okada; Srisin Khusmith; Naoto Keicho
Journal:  Int J Med Sci       Date:  2013-06-15       Impact factor: 3.738

4.  Circulating granulysin levels in healthcare workers and latent tuberculosis infection estimated using interferon-gamma release assays.

Authors:  Pham Huu Thuong; Do Bang Tam; Shinsaku Sakurada; Nguyen Thi Le Hang; Minako Hijikata; Le Thi Hong; Phan Thi Minh Ngoc; Pham Thu Anh; Vu Cao Cuong; Ikumi Matsushita; Luu Thi Lien; Naoto Keicho
Journal:  BMC Infect Dis       Date:  2016-10-18       Impact factor: 3.090

5.  Diminished Systemic and Mycobacterial Antigen Specific Anti-microbial Peptide Responses in Low Body Mass Index-Latent Tuberculosis Co-morbidity.

Authors:  Anuradha Rajamanickam; Saravanan Munisankar; Chandra Kumar Dolla; Subash Babu
Journal:  Front Cell Infect Microbiol       Date:  2020-04-28       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.